Hyperandrogenism, a main clinical feature of polycystic ovary syndrome (PCOS), is thought to result from enhanced ovarian and adrenal androgen generation. To investigate the contribution of peripheral steroidogenesis, we used an oral challenge with dehydroepiandrosterone (DHEA) and analyzed its downstream conversion toward androgens in eight women with PCOS (age, 20 -32 yr; body mass index, 20 -41 kg/m 2 ) and eight healthy women matched for age and body mass index. They underwent frequent serum sampling and urine collection for 8 h on three occasions: at baseline, and after 4 d of dexamethasone (Dex; 4 ؋ 0.5 mg/d), followed by ingestion of 100 mg DHEA or placebo. Dex induced similar significant suppression of circulating steroids in both groups. The oral DHEA challenge led to similar significant increases in the area under the concentration-time curve (0 -8 h after Dex) of serum DHEA, DHEA sulfate, androstenedione, and testosterone. However, after oral DHEA, PCOS women had significantly higher increases in serum 5␣-dihydrotestosterone (P < 0.01), its main metabolite androstanediol glucuronide (P < 0.05), and the 5␣-reduced urinary androgen metabolite androsterone (P < 0.05). PCOS women also had significantly higher baseline excretion of 5␣-reduced glucocorticoid (P < 0.01) and mineralocorticoid metabolites (P < 0.05). Taken H YPERANDROGENISM IS THE principal biochemical abnormality in women affected by the polycystic ovary syndrome (PCOS), the most common endocrine disorder in women of reproductive age (1, 2). However, the origin of hyperandrogenemia in PCOS still remains controversial (3). Acute ovarian stimulation with GnRH agonists elicits higher androgen responses in PCOS women (4, 5). Ovarian suppression with long-acting GnRH agonists leads to a significant decline in circulating androgens in both healthy and PCOS women (6 -8), but androgen levels remain higher in PCOS. Likewise, PCOS women show an exaggerated androgen response after adrenal stimulation with ACTH (9 -11); and, after adrenal suppression by dexamethasone (Dex), PCOS women still have higher circulating androgen levels than controls (12). Thus, it is generally accepted that both ovary and adrenal significantly contribute to hyperandrogenemia in PCOS. It has also been suggested that enhanced activity of the steroidogenic enzyme P450c17, which is expressed both in adrenal and ovary (13), may be responsible for hyperandrogenemia in PCOS (14, 15). The 17,20 lyase activity of P450c17 represents the crucial step in the biosynthesis of dehydroepiandrosterone (DHEA) (16), which is the mandatory precursor of human androgen synthesis. In vitro studies found increased androgen secretion by ovarian theca cells from PCOS patients (17, 18) and reported enhanced 5␣-reductase activity, i.e. conversion of testosterone (T) to 5␣-dihydrotestosterone (DHT), in ovarian follicles from PCOS women (18).
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YPERANDROGENISM IS THE principal biochemical abnormality in women affected by the polycystic ovary syndrome (PCOS), the most common endocrine disorder in women of reproductive age (1, 2) . However, the origin of hyperandrogenemia in PCOS still remains controversial (3) . Acute ovarian stimulation with GnRH agonists elicits higher androgen responses in PCOS women (4, 5) . Ovarian suppression with long-acting GnRH agonists leads to a significant decline in circulating androgens in both healthy and PCOS women (6 -8) , but androgen levels remain higher in PCOS. Likewise, PCOS women show an exaggerated androgen response after adrenal stimulation with ACTH (9 -11); and, after adrenal suppression by dexamethasone (Dex), PCOS women still have higher circulating androgen levels than controls (12) . Thus, it is generally accepted that both ovary and adrenal significantly contribute to hyperandrogenemia in PCOS. It has also been suggested that enhanced activity of the steroidogenic enzyme P450c17, which is expressed both in adrenal and ovary (13) , may be responsible for hyperandrogenemia in PCOS (14, 15) . The 17,20 lyase activity of P450c17 represents the crucial step in the biosynthesis of dehydroepiandrosterone (DHEA) (16) , which is the mandatory precursor of human androgen synthesis. In vitro studies found increased androgen secretion by ovarian theca cells from PCOS patients (17, 18) and reported enhanced 5␣-reductase activity, i.e. conversion of testosterone (T) to 5␣-dihydrotestosterone (DHT), in ovarian follicles from PCOS women (18) .
However, beyond increased adrenal and ovarian androgen synthesis, there may be an important contribution of peripheral androgen synthesis to hyperandrogenism in PCOS. Stewart et al. (19) reported a significantly increased urinary baseline excretion of 5␣-reduced androgen and glucocorticoid metabolites in women with PCOS, thereby providing indirect evidence for increased peripheral 5␣-reductase activity. We have previously shown that orally administered DHEA is readily converted to androgens (Fig.  1 ) in women, looking both at healthy women with transient adrenal suppression by Dex (20) and at women with chronic adrenal insufficiency (21) . Therefore, we used an oral challenge with DHEA as a diagnostic tool to clarify whether downstream conversion of DHEA toward androgens differs between healthy women and women with PCOS.
Subjects and Methods Subjects
Eight women with PCOS (age range, 20 -32 yr; median body mass index, 25.7 kg/m 2 ; range, 20.3-41.3 kg/m 2 ) were recruited from the outpatient clinic of a secondary/tertiary care referral unit. In all patients, diagnosis of PCOS was established by fulfillment of the following two Abbreviations: A'dione, 4-Androstene-3,17-dione; ADG, 5␣-androstane-3␣,17␤-diol-17-glucuronide; An, androsterone; AUC (0 -8 h) , area under the curve (0 -8 h); Dex, dexamethasone; DHEA, dehydroepiandrosterone; DHEAS, DHEA sulfate; DHT, 5␣-dihydrotestosterone; E2, 17␤-estradiol; Et, etiocholanolone; GC-MS, gas chromatographic-mass spectrometric; PCOS, polycystic ovary syndrome; T, testosterone; THA, tetrahydro-11-dehydrocorticosterone; THB, tetrahydrocorticosterone; THE, tetrahydrocortisone; THF, tetrahydrocortisol. criteria: first, clinical evidence of hirsutism (seven of eight patients presented with a Ferriman-Gallwey score more than 8) and/or oligo-/ ameneorrhea (5/8); second, hyperandrogenemia [i.e. serum concentrations of DHEA sulfate (DHEAS) (5/8), androstenedione (7/8), and/or T (6/8) above the normal range for females]. In addition, all patients showed an elevated LH/FSH ratio (i.e. more than 1.5 at baseline and/or more than 3.0 after stimulation with 100 g GnRH iv). Eight healthy control subjects were recruited via local advertising and were matched for sex, age, and body mass index (median, 24.5 kg/m 2 ; range, 19.8 -37.8 kg/m 2 ). All controls had regular menstrual cycles; normal serum concentrations of DHEAS, androstenedione, and T; and no evidence of hirsutism. Further inclusion criteria for both groups were: normal blood cell counts, and normal hepatic and renal function parameters. Exclusion criteria for both patients and controls were: evidence of 21-hydroxylase deficiency or 3␤-hydroxysteroid dehydrogenase deficiency, hyperprolactinemia, hypo-or hyperthyroidism, diabetes mellitus, pregnancy, current or previous intake of antiandrogenic drugs, current or previous long-term glucocorticoid treatment, current intake of drugs known to induce hepatic P450 enzymes, and current intake of oral contraceptives. Before the initiation of the study, the protocol had been approved by the Ethics Committee of the University of Wuerzburg, and written informed consent was obtained from all study participants.
Study protocol
The study was performed in a single-dose, randomized, cross-over design. All participants were studied during the early follicular phase of three subsequent cycles; in oligo-/amenorrhoic subjects, study days were separated by 4 wk. Cycle 1 served as baseline. Preceding the study days during cycles 2 and 3, all subjects were pretreated with oral Dex (4 ϫ 0.5 mg daily for 4 d). On study d 2 and 3, either placebo or 100 mg DHEA (25-mg capsules, Natrol) were administered orally at 0900 h in a randomized order. On all three study days, frequent blood sampling was performed, starting after an overnight fast at 0830 h (Ϫ30 min), followed by sampling at 0, 30, 60, 90, 120, 150, 180, 240, 300, 360, and 480 min. In addition, all participants collected their urine from 0900 h till 1700 h. Standardized meals were served at 1030 h and 1500 h. Cross-reactivities to other steroids relevant to this study were less than 0.01%. For all assays, the intra-and interassay coefficients of variation were less than 8% and less than 12%, respectively. Urinary steroid profiles were determined using quantitative data produced by gas chromatographic-mass spectrometric (GC-MS) analysis according to the method described by Shackleton (22) . In brief, free and conjugated urinary steroids were extracted by solid-phase extraction, and the conjugates were enzymatically hydrolyzed, followed by recovery of the hydrolyzed steroids by Sep-Pak (Waters, Milford, MA) extraction. Known amounts of three internal standards (5␣-androstane-3␣,17␣-diol; stigmasterol; and cholesteryl butyrate) were added to a portion of each extract before formation of methyloxime-trimethylsilyl ethers. Gas chromatography was performed using an Optima-1 fused silica column. Helium was used as carrier gas. The gas chromatograph (Agilent 6890 Series GC; Agilent 7683 Series Injector, Agilent Technologies, Boehlingen, Germany) was directly interfaced to a mass selective detector (Agilent 5973N MSD) operated in selected ion-monitoring mode. Calibration of the GC-MS was achieved by analysis of a reference mixture containing known amounts of all of the separation compounds. The injections took place with an 80 C (2 min) gas chromatography oven; the temperature was then increased by 20 C/min to 190 C (1 min). Then, for separation of steroids, it was increased by 2.5 C/min to 272 C. After calibration, values for the excretion of individual steroids were determined by measuring the selected ion peak areas against the internal standards.
Measurements

Statistics
All data are reported as mean Ϯ sem. The area under the concentrationtime curve, 0 -8 h [AUC (0 -8 h) ] for the measured serum steroid hormones was calculated by means of trapezoidal integration. The normal distribution of results was ascertained by using the Kolmogorov-Smirnov-Lilliefors test. Thus, comparisons between PCOS and control groups were carried out by t test for unpaired samples, and comparisons of results at baseline and after DHEA, within each group, were performed by t test for paired samples. Significance was defined as P Ͻ 0.05.
Results
Serum hormones at baseline
As expected, women with PCOS had significantly higher baseline concentrations of serum DHEA, A'dione, and T; serum DHEAS, DHT, and ADG showed a trend toward significant difference (all P Ͻ 0.1) ( Table 1) . By contrast, serum cortisol was nearly identical in the two groups (PCOS vs. controls: AUC (0 -8 h) 2611 Ϯ 156 vs. 2403 Ϯ 214 nm ϫ h, not significant; to convert nm ϫ h to g/dl ϫ h, divide by 27.59).
Serum hormones after Dex
Pretreatment with Dex led to a lasting and pronounced suppression of serum DHEA, DHEAS, A'dione, T, DHT, and ADG, both in women with PCOS and in healthy controls (Table 1) . Comparing the changes in mean AUC (0 -8 h) values, there was a slightly higher suppression of serum DHEA in PCOS than in controls (P Ͻ 0.05) but a similar suppression of serum DHEAS and A'dione ( Table 2) . PCOS women showed somewhat less suppression of serum T, DHT, and ADG; however, this was not significant, because of a considerable amount of interindividual variability in response to Dex (in particular, within the PCOS group) ( Table 2 ). This may also explain why there was no significant difference between PCOS and controls with regard to absolute levels of serum hormones after Dex, with the exception of serum T [AUC (0 -8 h) PCOS vs. controls: 8.2 Ϯ 2.8 vs. 1.5 Ϯ 0.4 nm ϫ h, P Ͻ 0.05; to convert nm ϫ h to ng/ml ϫ h, divide by 3.467] and the DHT main metabolite ADG (38 Ϯ 7 vs. 18 Ϯ 5 nm ϫ h, P Ͻ 0.05; to convert nm ϫ h to ng/ml ϫ h, divide by 2.13), which both remained significantly higher in PCOS (Table 1) .
Serum hormones after DHEA
After oral administration of 100 mg DHEA, serum levels of DHEA, DHEAS, and A'dione rose to a similar extent in PCOS and controls (Fig. 2) , with no significant difference in AUC (0 -8 h) between the groups after correction for the Dexsuppressed baseline (Table 1) . Also, the expected increase in serum T was nearly identical between PCOS and controls (Fig. 3) . By contrast, PCOS women exhibited significantly higher increases in serum DHT (P Ͻ 0.01) and in the major DHT metabolite ADG (P Ͻ 0.05) after DHEA ingestion (Fig.  3) . Correction for Dex-suppressed baselines (Fig. 4) further illustrates this increase in the androgenic pool downstream from the catalytic activity of 5␣-reductase, the enzyme that converts T to DHT.
FIG. 3. Mean serum concentrations (ϮSEM) of T (A), DHT (B)
, and 5␣-androstane-3␣,17␤-diol glucuronide (C) in women with PCOS (n ϭ 8) and in controls (n ϭ 8) at baseline (-f-), after 4 d of Dex (4 ϫ 0.5 mg/d) (-OE-), and after 4 d of Dex followed by the ingestion of a single dose of 100 mg DHEA (-ࡗ-). To convert the values for T to ng/ml, divide nM by 3.467; to convert values for DHT to ng/ml, divide nM by 3.467; to convert values for 5␣-androstane-3␣,17␤-diol-17-glucuronide to ng/ml, divide nM by 2.13.
Urinary steroid metabolites
As expected, PCOS women had a significantly higher baseline excretion of androgen metabolites than did controls [androsterone (An) ϩ etiocholanolone (Et): 5940 Ϯ 1161 vs. 2030 Ϯ 385 g/8 h, P Ͻ 0.05], reflecting the significantly higher levels of serum androgens in PCOS. However, despite similar AUC (0 -8 h) values for serum cortisol in both groups, baseline excretion of glucocorticoid metabolites [sum of tetrahydrocortisone (THE), tetrahydrocortisol (THF), 5␣-THF, cortoles, and cortolones] and mineralocorticoid metabolites [sum of tetrahydro-11-dehydrocorticosterone (THA), tetrahydrocorticosterone (THB), and 5␣-THB] was significantly increased in PCOS women (Fig. 5) . After Dex pretreatment, glucocorticoid and mineralocorticoid metabolites were suppressed down to around 10% of baseline levels, and androgen metabolites decreased to 15-30% of baseline levels in both groups (Table 3) . After the oral DHEA challenge, the 5␣-reduced androgen metabolite An increase was significantly higher in PCOS than in controls (5308 Ϯ 1385 vs. 2633 Ϯ 253 g/8 h, P Ͻ 0.05), whereas the increase in the 5␤-reduced androgen metabolite Et failed to become significant (Table 3) . However, because of considerable interindividual variations in urinary steroid excretion, the calculation of the ratios of 5␣-THF to 5␤-THF and of An to Et, which are considered to be approximate measures of net 5␣-reductase activity, did not reveal a significant difference between PCOS and controls.
Discussion
We successfully used an oral challenge with DHEA as a tool to unmask significant differences in peripheral androgen activation between women with PCOS and healthy controls. Our results intriguingly suggest an increased 5␣-reductase activity in women with PCOS, as schematically illustrated in Fig. 6 . Exogenous DHEA administration resulted in enhanced generation of serum DHT, which is generated from T by 5␣-reductase, and of its major metabolite ADG. Concurrently, urinary excretion of the 5␣-reduced androgen metabolite An after DHEA administration was significantly higher in PCOS. All these changes are readily explained by increased peripheral 5␣-reductase activity. Interestingly, this difference became more readily apparent after the oral DHEA challenge. This may indicate the superiority of this dynamic intracrine test over the measurement of baseline concentrations, which only represent a net measure of enzymatic activities.
PCOS women also had a significantly higher baseline excretion of 5␣-reduced glucocorticoid and mineralocorticoid metabolites. Though the ratios of 5␣-to 5␤-reduced steroid metabolites failed to become significantly different in our study, this may have been mainly attributable to the generally considerable interindividual variation in urinary steroid excretion rates and the relatively low number of subjects in our study (n ϭ 8). In keeping with our findings, another recent study in only 9 patients with PCOS also found a significantly increased excretion of total glucocorticoid metabolites, whereas the differences in the ratios of 5␣-to 5␤- reduced steroids failed to become significant (23) . Stewart et al. (19) analyzed urinary steroid excretion in 11 patients and were the first to report an increased ratio of 5␣-to 5␤-reduced glucocorticoid and androgen metabolites in PCOS. The validity of these findings was confirmed by the results of a recent (and so far, largest) study on urinary steroid excretion in 98 women with PCOS (24) . However, our study is the first to report significantly increased excretion of 5␣-and 5␤-reduced mineralocorticoid metabolites. The pathophysiological consequences of enhanced glucocorticoid and mineralocorticoid metabolism in PCOS remain elusive. Because serum cortisol did not differ between PCOS and controls, an enhanced generation of glucocorticoids, and possibly also of mineralocorticoids, in PCOS may try to compensate for the faster metabolism. Whether excess generation of gluco-and mineralocorticoids also leads to a biologically relevant increase in receptor binding (with a potential impact on blood pressure and glucose tolerance) remains to be speculated. Stewart et al. (19) suggested that enhanced clearance of cortisol caused by increased 5␣-reductase activity could lead to a counterregulatory activation of the HPA axis and thus to enhanced adrenal androgen generation. However, they failed to demonstrate an increase in ACTH secretion or pulsatility in a follow-up study (25) .
An increase in 5␣-reductase activity will inevitably lead to enhanced androgen activation by conversion of T to DHT in peripheral target cells of androgen action. This clearly points toward the importance of the relative contributions of liver and peripheral target tissues to enhanced androgen generation in PCOS. In our study, adrenal androgen generation was suppressed by Dex; and, though DHEAS has been suggested to be a precursor for ovarian steroidogenesis (26), our findings are unlikely to be explained by increased ovarian uptake of DHEA. More probable, they are the result of enhanced androgen synthesis outside ovary and adrenal, e.g. liver, skin, and other peripheral target tissues of androgen action. It is conceivable that enhanced 5␣-reductase activity and increased androgen synthesis are interrelated events, e.g. by transcriptional regulation of 5␣-reductase expression by androgens and their precursors.
The importance of the periphery is underlined by the significant increase in the major DHT metabolite ADG (27) after the DHEA challenge in our PCOS women. Serum ADG concentrations are a good measure of intracrine androgen activation (28) , i.e. the generation and subsequent metabolism of DHT within one-and-the-same peripheral target cell. This does not become readily apparent by an increase in circulating DHT but rather by an increase in serum ADG (29) , because DHT will only reenter the bloodstream after it has been metabolized to ADG. The concept of enhanced peripheral androgen generation by 5␣-reductase is further supported by results from previous studies showing increased FIG. 6 . Schematic summary of the observed differences between PCOS and control women (serum steroids after Dex pretreatment followed by oral DHEA challenge; urinary steroid excretion at baseline). GC, Glucocorticoid; MC, mineralocorticoid. 5␣-reductase activity in skin biopsies from hirsute women (30, 31) , which correlates with increased ADG production (32).
In conclusion, our results are highly suggestive of an increased peripheral 5␣-reductase activity in women with PCOS and thus of a significant contribution of peripheral and intrahepatic steroidogenesis to the steroid changes observed in PCOS. This may shift our view on PCOS, beyond ovary and adrenal, to the modulation of steroidogenesis at the prereceptor level in most, if not all, peripheral target cells of steroid action.
